Академический Документы
Профессиональный Документы
Культура Документы
Página 1 de 2
Generated by Foxit PDF Creator © Foxit Software
http://www.foxitsoftware.com For evaluation only.
Source: PharmacoEconomics, Volume 17, Number 1, January 2000 , pp. 77-107(31)
Publisher: Adis International
Abstract:
Objective: This paper examined the economic cost of male erectile dysfunction (ED) for a
hypothetical managed-care (MC) model.
Participants: A total of 100 000 enrolled members were included in the study.
Conclusions: Sildenafil and the vacuum erection device should be considered as first-line
management strategies for ED whereas ICI therapy, transurethral alprostadil suppository and penile
prosthesis implant should be reserved for second- or third-line therapy. Because costs associated
with switches related to successive treatment failures can be high, treatment considerations should,
therefore, focus on achieving long term patient satisfaction. The patient's preferred treatment choice,
using goal-directed therapy during the initial consultation and evaluation visit, should be used.
http://www.ingentaconnect.com/content/adis/pec/2000/00000017/00000001/art00006;jses... 13/06/2010
IngentaConnect Economic Cost of Male Erectile Dysfunction Using a Decision Analyti... Página 2 de 2
Generated by Foxit PDF Creator © Foxit Software
http://www.foxitsoftware.com For evaluation only.
Keywords: Alprostadil, therapeutic use; Clinical trial design; Cost analysis; Erectile dysfunction,
treatment; Pharmacoeconomics; Sildenafil, therapeutic use; Testosterone, therapeutic use
Language: English
Document Type: Original article
Affiliations: 1: Health Outcomes Research Design Consultants LLC, Dover, Delaware, USA *
• http://www.ingentaconnect.com/adis/pec/2000/00000017/00000001/art00006
• http://openurl.ingenta.com/content?genre=article&issn=1170-
7690&volume=17&issue=1&spage=77&epage=107
http://www.ingentaconnect.com/content/adis/pec/2000/00000017/00000001/art00006;jses... 13/06/2010